Compare Kinross Gold Corporation (KGC) vs Tango Therapeutics Inc. (TNGX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Kinross Gold Corporation vs Tango Therapeutics Inc. — how do they compare? Kinross Gold Corporation trades at $22.45 (market cap $27.68B), while Tango Therapeutics Inc. trades at $22.23 (market cap $3.75B). The key difference: Kinross Gold Corporation is far larger — about 7.4× Tango Therapeutics Inc.'s market cap, and Kinross Gold Corporation pays a 0.68% dividend while Tango Therapeutics Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Kinross Gold Corporation for 53 Days and Tango Therapeutics Inc. for 0 Days on average.
| KGC | TNGX | |
|---|---|---|
Market Cap | $27.68B | $3.75B |
Volume | 5,395,404 | 9,619,106 |
Sector | Basic Materials | Health |
52-Week High | $38.06 | $32.90 |
52-Week Low | $22.24 | $7.50 |
Typical Hold Time | 53 Days | 0 Days |
Enterprise Value | $25.76B | $2.77B |
Dividend Yield | 0.68% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Kinross Gold (KGC) trades at $22.24, down 5.56% amid production guidance cuts and legal investigations, yet maintains strong fundamentals with robust earnings beats and a 37.52% net margin. Technical indicators show bearish momentum with support at $23, while fundamentals reveal impressive revenue growth from $3.5B in 2022 to $7.05B in 2025, supported by a low P/E of 8.91 and rising cash flow.
The stock presents a value opportunity with a consensus price target of $38.80 (74% upside), but faces near-term headwinds from operational setbacks and legal scrutiny. Long-term prospects remain solid due to gold price strength and shareholder returns, though investors must weigh production risks against valuation appeal.
TNGX trades at $22.22, down 8.07% in the last session, reflecting negative investor reaction to recent earnings misses. The stock shows neutral technical signals with key support at $21 and resistance at $23. Fundamentally, the company maintains a high gross margin of 98.25% but faces significant losses with a net income margin of -229.92% and negative cash flow from operations. Recent news highlights institutional buying interest and upcoming clinical trial developments.
Despite strong analyst support with a $45.91 consensus price target (107% upside), TNGX faces substantial execution risks as a clinical-stage biotech. The company's heavy cash burn and lack of profitability require careful monitoring of pipeline progress. Investment appeal hinges on successful drug development outcomes rather than current financial metrics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Kinross Gold Corporation
Kinross Gold is a Canada-based senior gold producer, producing roughly 2.4 million gold equivalent ounces in 2020. The company had 30 million ounces of proven and probable gold reserves and 59 million ounces of silver reserves at the end of 2020. It operates mines and focuses its greenfield and brownfield exploration in the Americas, West Africa, and Russia. The company has historically used acquisitions to fuel expansion into new regions and production growth.
Read more on KGC →About Tango Therapeutics Inc.
Tango Therapeutics, Inc. is a clinical-stage biotechnology company focused on precision oncology, developing cancer therapies based on the genetic principle of synthetic lethality, including its PRMT5 inhibitor program.
Read more on TNGX →
